Dr. Michael Weiss is Professor of Neurology, founding Director of the Division of Neuromuscular Diseases, and Director of the MDA/ALS Clinic at the University of Washington Medical Center. He received his undergraduate degree from Brown University and his medical degree from the Albert Einstein College of Medicine. He then did his neurology training at Georgetown University Hospital and a fellowship in neuromuscular disease at the University of Maryland Medical Center. Dr. Weiss has been an active NEALS member since 2008, participating in a number of treatment trials and biomarker studies, including recently dexpramipexole, creatine-tamoxifen, and the CABB study. He is particularly interested in the role of neuronal hyperexcitability in ALS and was the principal investigator for a recently completed multicenter study using the drug mexiletine that was found to dramatically reduce muscle cramps in patients. With the help of the NEALS, he recently launched another mexiletine study aimed at assessing pharmacodynamics markers of neuronal hyperexcitability using transcranial magnetic stimulation and threshold tracking nerve conduction study to determine if the drug can potentially slow the disease.